OncoOne is a biotech start-up dedicated to develop innovative therapeutics to treat patients with solid tumors.
OncoOne currently has three drug candidates for four indications (colorectal, pancreatic, ovarian and lung cancers).
OncoOne was founded in June 2018 by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl. The company is headquartered in Klosterneuburg, Lower Austria, Austria.
OncoOne aims to be a research engine for anti-cancer medicines that meet serious unmet medical needs in oncology.
OncoOne seeks to overcome the limitations of targeting macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform, oxidized macrophage migration inhibitory factor (oxMIF).
OncoOne is focused on developing multiple proprietary drug modalities to leverage oxMIF’s potential as a target for systemic treatment of pancreatic, colorectal, ovarian and lung cancer.
OncoOne was launched with €13M ($14.26M) in a Series A round on Mar 18, 2020. The investment was backed by Baxter Healthcare and Shire Pharmaceuticals.